DNLI vs. IMCR, TWST, ACLX, IOVA, SWTX, VCEL, RXRX, APGE, KYMR, and ADMA
Should you be buying Denali Therapeutics stock or one of its competitors? The main competitors of Denali Therapeutics include Immunocore (IMCR), Twist Bioscience (TWST), Arcellx (ACLX), Iovance Biotherapeutics (IOVA), SpringWorks Therapeutics (SWTX), Vericel (VCEL), Recursion Pharmaceuticals (RXRX), Apogee Therapeutics (APGE), Kymera Therapeutics (KYMR), and ADMA Biologics (ADMA). These companies are all part of the "biological products, except diagnostic" industry.
Immunocore (NASDAQ:IMCR) and Denali Therapeutics (NASDAQ:DNLI) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, community ranking, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.
Immunocore has a net margin of -22.60% compared to Immunocore's net margin of -36.51%. Immunocore's return on equity of -11.46% beat Denali Therapeutics' return on equity.
Denali Therapeutics received 391 more outperform votes than Immunocore when rated by MarketBeat users. However, 70.59% of users gave Immunocore an outperform vote while only 67.43% of users gave Denali Therapeutics an outperform vote.
Immunocore has higher earnings, but lower revenue than Denali Therapeutics. Immunocore is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Immunocore had 1 more articles in the media than Denali Therapeutics. MarketBeat recorded 11 mentions for Immunocore and 10 mentions for Denali Therapeutics. Immunocore's average media sentiment score of 0.49 beat Denali Therapeutics' score of 0.13 indicating that Denali Therapeutics is being referred to more favorably in the news media.
Immunocore currently has a consensus target price of $81.85, suggesting a potential upside of 53.38%. Denali Therapeutics has a consensus target price of $40.22, suggesting a potential upside of 97.75%. Given Immunocore's stronger consensus rating and higher possible upside, analysts plainly believe Denali Therapeutics is more favorable than Immunocore.
84.5% of Immunocore shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 9.1% of Immunocore shares are held by insiders. Comparatively, 7.9% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Immunocore has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.
Summary
Denali Therapeutics beats Immunocore on 10 of the 18 factors compared between the two stocks.
Get Denali Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Denali Therapeutics Competitors List
Related Companies and Tools
